Gregory Louie

The paper uses targeted metabolomics to analyze changes in acylcarnitines, amines, and lipids in response to citalopram/escitalopram treatment in MDD patients, identifying metabolic correlates of treatment response.

The paper identifies serum metabolites associated with brain amyloid-beta deposition, cognitive dysfunction, and progression to Alzheimer's disease.

The paper investigates sex and APOE ε4 genotype effects on metabolic alterations in Alzheimer’s disease using stratified analysis of serum metabolites.

This study identifies metabolites and pathways in serum and brain tissue associated with cognitive impairment and develops models to predict antecedent cognitive decline in older adults.

The paper identifies differences in bile acid pathways for cholesterol clearance in Alzheimer’s disease by analyzing transcriptomes and metabolomics data from brain samples.

This study identifies metabolomic clusters associated with depressive symptom change and treatment response to CBT in MDD patients.

The paper identifies altered bile acid profiles in Alzheimer's disease, linking them to cognitive impairment and genetic variants through a large study.

The paper identifies associations between serum bile acid metabolites and AD biomarkers in the A/T/N framework, suggesting a potential role for bile acid pathways in AD pathophysiology.